M. Milhem

M. Milhem, J. Stein, D. Vaena, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Robin L. Jones, G. Demetri, H. Tawbi, 2015 .

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.

R. Sullivan, R. Dummer, J. Kirkwood, 2021, The New England journal of medicine.

Cancer immunotherapy: recent advances and challenges

U. Swami, M. Milhem, 2021, Annals of translational medicine.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Robin L. Jones, G. Demetri, H. Tawbi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trabectedin or dacarbazine for the treatment of patients with uterine leiomyosarcoma after prior chemotherapy: A subgroup analysis of the randomized phase 3 SAR-3007 study

Robin L. Jones, B. Monk, G. Demetri, 2016 .

Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents.

N. Mahmud, C. Beam, R. Hoffman, 2007, Experimental Hematology.

Alteration of Hematopoietic Stem Cell Fates by Chromatin‐Modifying Agents

N. Mahmud, R. Hoffman, M. Milhem, 2006 .

A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery.

G. T. Budd, Robin L. Jones, L. Qin, 2022, European journal of cancer.

Adhering to the guidelines: rates of BRCA mutation using NCCN genetic testing criteria

Jaime, Shaheen, J. Kirkwood, 2017 .

Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2015 .

Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer

B. Skikne, M. Abdelrahim, M. Milhem, 2020, Cancer Chemotherapy and Pharmacology.

Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy

M. Milhem, K. Wanat, Heather K Schopper, 2016, JAAD case reports.

Paclitaxel as Neoadjuvant Therapy for High Grade Angiosarcoma of the Spleen: a Brief Report and Literature Review

M. Milhem, B. Vakkalanka, 2010, Clinical Medicine Insights. Oncology.

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease

Y. Zakharia, M. Milhem, Sneha Phadke, 2016, Journal of investigative medicine high impact case reports.

Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

I. Puzanov, M. Milhem, H. Kaufman, 2014 .

Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

J. Blay, G. Demetri, A. Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor

H. Tawbi, V. Bolejack, D. Reinke, 2017, Cancer.

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

M. Ross, K. Delman, I. Puzanov, 2016, Annals of Surgical Oncology.

Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.

G. Linette, J. Wolchok, J. Sosman, 2014, JAMA.

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.

Y. Zakharia, U. Swami, A. Bossler, 2019, Melanoma research.

Presumed Melanoma of Unknown Primary Origin Metastatic to the Choroid Mimics Primary Uveal Melanoma

M. Milhem, Elaine M. Binkley, H. Boldt, 2021, Case Reports in Ophthalmology.

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

G. Linette, J. Wolchok, J. Sosman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts.

K. Harrington, A. Pavlick, T. Bowles, 2020 .

Status of the Clinician Investigator in America: An Essential Healthcare Provider Driving Advances in Cancer Care.

R. Holcombe, R. Goldberg, C. Verschraegen, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase Ib study of decitabine in combination with gemcitabine in treatment of advanced soft tissue and bone sarcomas.

M. Milhem, R. Dodd, S. Mott, 2020 .

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

G. Daniels, O. Guntinas-Lichius, M. Milhem, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

H. Colman, B. V. Van Tine, S. Guichard, 2022, Neuro-oncology.

Pityriasis lichenoides chronica–like drug eruption developing during pembrolizumab treatment for metastatic melanoma

M. Milhem, B. Swick, V. Liu, 2016, JAAD case reports.

514 Results of Phase 1b trial of the Indoleamine 2,3-dioxygenase (IDO) Pathway Inhibitor Indoximod plus Ipilimumab for the treatment of unresectable stage III or IV melanoma

D. Munn, C. Link, Y. Zakharia, 2015 .

The feasibility of using intravenous fentanyl as sublingual drops in the treatment of incidental pain in patients with cancer.

M. Milhem, Mohammad A Bushnaq, Muhannad Al-Shoubaki, 2009, Journal of Palliative Medicine.

Worsening solid facial edema: An unusual case of angiosarcoma

Nitin A. Pagedar, M. Milhem, K. Wanat, 2018, JAAD case reports.

Intralesional Methotrexate for Treatment of Invasive Squamous Cell Carcinomas in a Patient Taking Vemurafenib for Treatment of Metastatic Melanoma.

M. Milhem, M. V. Van Beek, M. Moye, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review

Y. Zakharia, U. Swami, M. Milhem, 2019, Cancers.

Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44

Aaron Bossler, Deborah Wessels, Daniel F Lusche, 2017, PloS one.

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma

Katie M. Campbell, D. Davar, J. Kirkwood, 2020 .

Current status of intralesional agents in treatment of malignant melanoma

Y. Zakharia, U. Swami, M. Milhem, 2021, Annals of translational medicine.

Oncolytic Virus Immunotherapy in Sarcoma

M. Milhem, V. Monga, S. Maliske, 2018, Immunotherapy of Sarcoma.

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.

C. Antonescu, G. Schwartz, W. Tap, 2018, The Lancet. Oncology.

Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide)

Brian J. Smith, R. Leon-Ferre, M. Milhem, 2014, Cancer Chemotherapy and Pharmacology.

Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A.

N. Mahmud, R. Hoffman, Y. Saunthararajah, 2004, Blood.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Dirk Schadendorf, Peter Mohr, Reinhard Dummer, 2012 .

Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial

Brian J. Smith, J. Buatti, Wenqing Sun, 2015, Head & neck.

SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017 .

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

J. Blay, Ruey-min Lee, G. Demetri, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors

Robin L. Jones, S. Steinberg, D. Reinke, 2017, Sarcoma.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)

D. Reinke, C. Meyer, L. Helman, 2019, Sarcoma.

Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Andrea R. Hallier, T. Braun, T. Chan, 2018, BMC Cancer.

Abstract CT117: Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma

D. Munn, R. McWilliams, C. Link, 2017 .

Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

D. Munn, R. McWilliams, C. Link, 2016 .

Plasma Angiopoietin 2 Concentrations Are Related to Impaired Lung Function and Organ Failure in a Clinical Cohort Receiving High-Dose Interleukin 2 Therapy

M. Monick, L. Powers, M. Milhem, 2014, Shock.

Signaling pathways in adenoid cystic cancers: Implications for treatment

J. Buatti, M. Milhem, Anjali K. Gupta, 2009, Cancer biology & therapy.

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TAZ and YAP are frequently activated oncoproteins in sarcomas

M. Milhem, M. Tanas, C. Stipp, 2016, Oncotarget.

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Y. Zakharia, M. Milhem, V. Monga, 2017, Future oncology.

A multi-center phase II study of high dose IL-2 (HD IL-2) sequenced with vemurafenib in patients with BRAF-V600E mutation positive advanced melanoma.

M. Ernstoff, M. Milhem, Joseph I. Clark, 2015 .

Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial

David M. Kuehn, J. Houtman, M. Milhem, 2021, Journal for ImmunoTherapy of Cancer.

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

D. Munn, R. McWilliams, R. Kolhe, 2021, Journal for ImmunoTherapy of Cancer.

The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma

J. Buatti, M. Milhem, C. Anderson, 2020, Radiation Research.

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma

A. Hauschild, I. Puzanov, C. Garbe, 2019, British Journal of Cancer.

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma

P. Frankel, M. Milhem, S. Okuno, 2019, Cancer.

Correlation of MTDH/AEG-1 and HOTAIR Expression with Metastasis and Response to Treatment in Sarcoma Patients.

K. Leslie, Xiangbing Meng, T. Knutson, 2011, Journal of cancer science & therapy.

Epigenetic Silencing of the Human NOS2 Gene: Rethinking the Role of Nitric Oxide in Human Macrophage Inflammatory Responses

F. Domann, M. Monick, L. Powers, 2014, The Journal of Immunology.

Human Macrophage Inflammatory Gene: Rethinking the Role of Nitric Oxide in NOS2 Epigenetic Silencing of the Human

F. Domann, L. Powers, T. Knutson, 2014 .

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Brian J. Smith, U. Swami, A. Bossler, 2018, Cancers.

423 Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors

M. Burgess, C. Kelly, A. Daud, 2020 .

Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance

M. Milhem, R. Dodd, V. Monga, 2022, Cancer drug resistance.

Sorafenib for Advanced and Refractory Desmoid Tumors

Narasimhan P. Agaram, L. Schwartz, E. Basch, 2018, The New England journal of medicine.

422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts

K. Harrington, A. Pavlick, T. Bowles, 2020 .

The clinical characteristics of melanoma with BRAF V600R mutation: a case series study

Y. Zakharia, M. Milhem, Anthony N. Snow, 2020, Melanoma research.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

N. Agarwal, M. Fishman, S. Patel, 2016, Clinical genitourinary cancer.

Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-Adaptation.

P. Breheny, Marion Vanneste, A. Rowat, 2020, Cell reports.

Gastrointestinal stromal tumors-are we stuck and the way forward.

U. Swami, M. Milhem, V. Monga, 2017, Translational gastroenterology and hepatology.

SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs).

S. Steinberg, D. Reinke, S. Schuetze, 2013 .

Advanced stage melanoma therapies: Detailing the present and exploring the future.

Y. Zakharia, U. Swami, M. Milhem, 2019, Critical reviews in oncology/hematology.

Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature

Y. Zakharia, M. Milhem, K. Malkhasyan, 2017, Pigment cell & melanoma research.

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

M. Ross, K. Harrington, J. Nemunaitis, 2016, Head & neck.

Improved survival for extremity soft tissue sarcoma treated in high‐volume facilities

M. Milhem, M. Tanas, Yubo Gao, 2018, Journal of surgical oncology.

An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.

B. V. Van Tine, A. Hirbe, M. Milhem, 2021, European journal of cancer.

A rare case series of composite hemangioendothelioma presenting as bone tumors

A. Bellizzi, M. Milhem, B. Miller, 2020 .

Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

G. Demetri, Tanmay Parekh, R. Maki, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis

Charlotte R. Feddersen, Marion Vanneste, K. Holt, 2020, Frontiers in Oncology.

Non-Conventional Treatments for Conventional Chondrosarcoma

A. Hirbe, M. Milhem, V. Monga, 2020, Cancers.

The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective Analysis

Y. Tao, A. Hirbe, Xiao Zhang, 2022, Genes.

A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.

C. Antonescu, G. Schwartz, W. Tap, 2020 .

Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).

Narasimhan P. Agaram, R. Maki, G. Schwartz, 2018 .

Expansion of human umbilical cord blood SCID-repopulating cells using chromatin-modifying agents

N. Mahmud, C. Beam, R. Hoffman, 2006 .

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study

Marion Vanneste, Y. Zakharia, U. Swami, 2017, Oncotarget.

Toxicities with targeted therapies after immunotherapy in metastatic melanoma

Y. Zakharia, U. Swami, A. Bossler, 2018, Melanoma research.

427 A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced melanoma

R. Garje, Hesham Yasin, Y. Zakharia, 2020 .

Leiomyosarcoma of the head and neck: a population-based analysis.

Nitin A. Pagedar, M. Milhem, B. Deyoung, 2011, Archives of otolaryngology--head & neck surgery.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

J. Utikal, D. Schadendorf, K. Flaherty, 2019, European journal of cancer.

Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma

M. Ross, I. Puzanov, M. Milhem, 2016 .

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

M. Ross, L. Aicher, R. Pierce, 2022, Cancer research communications.

Patient reported quality of life in young adults with sarcoma receiving care at a sarcoma center

M. Milhem, S. Mott, M. Tanas, 2022, Frontiers in Psychology.

Jordan palliative care initiative: a WHO Demonstration Project.

J. Stjernswärd, F. Ferris, M. Milhem, 2007, Journal of pain and symptom management.

Cancer cells resist mechanical destruction in the circulation via RhoA-myosin II axis

P. Breheny, Marion Vanneste, A. Rowat, 2019, bioRxiv.

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

B. V. Van Tine, A. Hirbe, I. Helenowski, 2018, British Journal of Cancer.

A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas

B. V. Van Tine, A. Hirbe, M. Milhem, 2020, Cancers.

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas

A. Rademaker, B. V. Van Tine, M. Milhem, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers*

Andrew K Godwin, M. Merchant, A. Godwin, 2017, Molecular & Cellular Proteomics.

Sentinel Node Biopsy for Head and Neck Desmoplastic Melanoma

Nitin A. Pagedar, M. Milhem, H. Hoffman, 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Cord blood stem cell expansion is permissive to epigenetic regulation and environmental cues.

N. Mahmud, D. Lavelle, M. Milhem, 2009, Experimental hematology.

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Katie M. Campbell, D. Davar, J. Kirkwood, 2021, Cancer discovery.

Treatment with tebentafusp beyond radiographic progressive disease (PD) in metastatic uveal melanoma (mUM).

J. Kirkwood, C. Watkins, L. Demidov, 2022, Journal of Clinical Oncology.

O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab

Katie M. Campbell, D. Davar, J. Kirkwood, 2020, Journal of Immunotherapy for Cancer.

A positive antinuclear antibody test predicts for a poor response to initial steroid therapy in adults with idiopathic thrombocytopenic purpura

M. Milhem, L. Zaru, Salah Abbasi, 2008, Annals of Hematology.

SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).

S. Steinberg, D. Reinke, C. Meyer, 2016 .

Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?

M. Milhem, J. Deutsch, 2015, Current clinical pharmacology.

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

R. Janssen, A. Ribas, G. Daniels, 2018, Journal of Clinical Oncology.

Phase 2 study of cobimetinib in combination with vemurafenib in active melanoma brain metastases (coBRIM-B).

J. Kirkwood, H. Tawbi, L. Butterfield, 2015 .

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

D. Munn, R. McWilliams, C. Link, 2018 .

950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma

D. Davar, J. Kirkwood, A. Ribas, 2021, Journal for ImmunoTherapy of Cancer.

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

R. Janssen, G. Daniels, O. Guntinas-Lichius, 2019, Journal of Clinical Oncology.

A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.

A. Rademaker, B. V. Van Tine, M. Milhem, 2017 .

Multicenter, open-label phase II study of daily oral regorafenib for chemotherapy-refractory, metastatic and locally advanced angiosarcoma.

A. Rademaker, B. V. Van Tine, M. Milhem, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.

E. Schmidt, R. Janssen, A. Ribas, 2019, Journal of Clinical Oncology.

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

K. Harrington, N. Senzer, K. Delman, 2014, Journal of Immunotherapy for Cancer.

The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma

B. V. Van Tine, A. Hirbe, M. Milhem, 2023, Journal of clinical medicine.

Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.

S. Piha-Paul, M. Milhem, D. Purkayastha, 2019, Journal of Clinical Oncology.

SU2C-SARC032: A phase II randomized controlled trial of neoadjuvant pembrolizumab with radiotherapy and adjuvant pembrolizumab for high-risk soft tissue sarcoma.

B. Brigman, M. Burgess, D. Reinke, 2018 .

Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma.

A. Hauschild, M. Ross, I. Puzanov, 2017 .

Melanoma Characteristics in Patients with a History of UV Tanning Bed Usage

Nitin A. Pagedar, M. Milhem, K. Truong, 2020, Annals of Otology, Rhinology and Laryngology.

AST-008: A novel approach to TLR9 agonism with PD-1 blockade for anti-PD-1 refractory Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (CSCC).

M. Milhem, T. Wise-Draper, Weston L. Daniel, 2020 .

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial

A. Hauschild, C. Garbe, P. Friedlander, 2023, Journal for ImmunoTherapy of Cancer.

Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients under active treatment with chemotherapy

M. Milhem, S. Mott, V. Monga, 2018, European journal of cancer care.

Surgical management for giant bladder leiomyosarcoma

M. Milhem, V. Packiam, Charles H. Schlaepfer, 2022, Urology case reports.

The prevalence and significance of radiographic incidental findings during initial staging of melanoma: a retrospective study

M. Milhem, S. Mott, V. Liu, 2020, Journal of the European Academy of Dermatology and Venereology.

Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report

Nitin A. Pagedar, M. Milhem, C. Anderson, 2018, Head & neck.

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.

H. Colman, M. Milhem, M. Rosenthal, 2020 .

Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.

D. Schadendorf, J. Hou, M. Middleton, 2023, Journal of Clinical Oncology.

Correction to: Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy

Andrea R. Hallier, N. Rizvi, A. Bossler, 2018, BMC Cancer.

Melanoma cells undergo aggressive coalescence in a 3D Matrigel model that is repressed by anti-CD44

Daniel F Lusche, E. Voss, D. Soll, 2017, PLoS ONE.

1265 Vedolizumab plus anti-PD1 antibody in advanced melanoma patients with inflammatory enterocolitis

Y. Zakharia, M. Milhem, Asad Javed, 2022, Regular and Young Investigator Award Abstracts.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

G. Linette, M. Ross, K. Harrington, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plasma Angiopoietin 2 Concentrations Are Related to Impaired Lung Function and Organ Failure in a Clinical Cohort Receiving High-Dose Interleukin 2 Therapy

M. Monick, M. Milhem, K. Doerschug, 2014, Shock.

Epigenetic Silencing of the Human NOS2 Gene: Rethinking the Role of Nitric Oxide in Human Macrophage Inflammatory Responses

F. Domann, M. Monick, T. Knutson, 2014, The Journal of Immunology.

Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas

B. V. Van Tine, A. Hirbe, I. Helenowski, 2021, British Journal of Cancer.

Clinical diagnostic and radiographic features of recurrent intracranial malignant triton tumor in an adult: illustrative case

M. Milhem, A. Belzer, J. Vivanco-Suarez, 2023, Journal of neurosurgery. Case lessons.

Post-operative echography for optimization of radiation dosimetry in patients with uveal melanoma treated with plaque brachytherapy.

M. Milhem, S. Mott, Elaine M. Binkley, 2023, Ophthalmology. Retina.

A phase II study of pazopanib with oral topotecan in patients with metastatic osteosarcoma.

A. Rademaker, B. V. Van Tine, M. Milhem, 2018, Annals of Oncology.

Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.

J. Blay, G. Demetri, A. Cesne, 2012 .